Renal cell carcinoma treatment after first-line combinations
Porta C, Schmidinger M.
The Lancet, Vol 20, 10, P1332-1334, October 2019
Treatment of metastatic renal cell carcinoma has dramatically changed in the past two decades, moving from cytokine-based immunotherapy, to vascular endothelial growth factor (VEGF) pathway inhibitors, and to combinations of these inhibitors with novel immune checkpoint inhibitors. What was once defined as an “embarassment of riches” has now reached new, unexpected heights.